Entrada Therapeutics Inc (TRDA)
13.16
-0.40
(-2.95%)
USD |
NASDAQ |
May 03, 16:00
13.22
+0.06
(+0.46%)
Pre-Market: 20:00
Entrada Therapeutics PS Ratio: 3.409 for May 3, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| May 03, 2024 | 3.409 |
| May 02, 2024 | 3.513 |
| May 01, 2024 | 3.432 |
| April 30, 2024 | 3.070 |
| April 29, 2024 | 3.197 |
| April 26, 2024 | 3.225 |
| April 25, 2024 | 3.202 |
| April 24, 2024 | 3.22 |
| April 23, 2024 | 3.339 |
| April 22, 2024 | 3.394 |
| April 19, 2024 | 3.148 |
| April 18, 2024 | 3.085 |
| April 17, 2024 | 3.166 |
| April 16, 2024 | 3.295 |
| April 15, 2024 | 3.339 |
| April 12, 2024 | 3.355 |
| April 11, 2024 | 3.435 |
| April 10, 2024 | 3.243 |
| April 09, 2024 | 3.440 |
| April 08, 2024 | 3.484 |
| April 05, 2024 | 3.578 |
| April 04, 2024 | 3.583 |
| April 03, 2024 | 3.578 |
| April 02, 2024 | 3.596 |
| April 01, 2024 | 3.565 |
| Date | Value |
|---|---|
| March 28, 2024 | 3.671 |
| March 27, 2024 | 3.717 |
| March 26, 2024 | 3.565 |
| March 25, 2024 | 3.466 |
| March 22, 2024 | 3.554 |
| March 21, 2024 | 3.508 |
| March 20, 2024 | 3.458 |
| March 19, 2024 | 3.29 |
| March 18, 2024 | 3.215 |
| March 15, 2024 | 3.311 |
| March 14, 2024 | 3.160 |
| March 13, 2024 | 3.293 |
| March 12, 2024 | 3.000 |
| March 11, 2024 | 3.046 |
| March 08, 2024 | 3.285 |
| March 07, 2024 | 3.259 |
| March 06, 2024 | 3.210 |
| March 05, 2024 | 3.181 |
| March 04, 2024 | 3.207 |
| March 01, 2024 | 3.557 |
| February 29, 2024 | 3.427 |
| February 28, 2024 | 3.365 |
| February 27, 2024 | 3.536 |
| February 26, 2024 | 3.580 |
| February 23, 2024 | 3.458 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
3.000
Minimum
Mar 12 2024
4.404
Maximum
Jan 09 2024
3.578
Average
3.557
Median
Mar 01 2024
PS Ratio Benchmarks
| GlycoMimetics Inc | -- |
| Lyell Immunopharma Inc | 4556.23 |
| Candel Therapeutics Inc | 2104.81 |
| Eliem Therapeutics Inc | -- |
| NovaBay Pharmaceuticals Inc | 0.034 |
PS Ratio Related Metrics
| Price to Book Value | 1.824 |
| Price to Free Cash Flow | 3.278 |
| Price | 13.16 |
| Earnings Yield | -1.98% |
| Market Cap | 442.19M |